The news of Eric Dane’s death on Thursday at 53 came as a shock, but what’s unsettled many further is the reported speed of his illness. The actor, widely recognised for playing McSteamy on Grey’s ...

- AMX0114 is an Amylyx-developed antisense oligonucleotide designed to target calpain-2, a key contributor to the axonal degeneration pathway in ALS - Phase 1 LUMINA trial of AMX0114 underway; early ...

- AMX0114 is an Amylyx-developed antisense oligonucleotide designed to target calpain-2, a key contributor to the axonal degeneration pathway in ALS “Obtaining FDA Fast Track designation for AMX0114 ...

Darin Nakakihara doesn’t remember much from the day that changed his life. He left the doctor’s office and walked to his car. In the driver’s seat, he looked up the disease he was just diagnosed with, ...

New hope could be on the horizon for ALS patients in the form of a "breakthrough" drug, researchers say. Neuvivo, a California biopharmaceutical company that develops therapies for neurodegenerative ...

Please provide your email address to receive an email when new articles are posted on . AMX0114 was developed to target calpain-2, a driver of axonal neurodegeneration. A pending clinical trial will ...

The first platform trial for amyotrophic lateral sclerosis (ALS), which individually evaluated four experimental drugs, failed to meet key primary endpoints. Still, investigators view the trial as ...

Eric Dane advocated for a cure for Amyotrophic Lateral Sclerosis (ALS) as the progression of his symptoms was on full display in a campaign video. After the “Euphoria” actor missed the planned “Grey’s ...